Parkland
Community Health Plan

April 13, 2023

Makena Products No Longer Covered as of April 7, 2023

On April 6, 2023, the U.S. Food and Drug Administration announced that it has withdrawn its approval of Makena. This means that as of April 7, 2023, HHSC no longer covers the following Makena products or their clinical prior authorization.

NDC	Drug Name
64011030103	MAKENA 275 MG/1.1 ML AUTOINJCT
00517176701	HYDROXYPROGEST 250 MG/ML VIAL
55150030901	HYDROXYPROGEST 250 MG/ML VIAL
64011030103	MAKENA 275 MG/1.1 ML AUTOINJCT
67457096701	HYDROXYPROGEST 250 MG/ML VIAL
69238179701	HYDROXYPROGEST 250 MG/ML VIAL
71225010401	HYDROXYPROGEST 1,250 MG/5 ML
71225010501	HYDROXYPROGEST 250 MG/ML VIAL

Los productos de Makena ya no están cubiertos a partir del 7 de abril de 2023

El 6 de abril de 2023, la Administración de Drogas y Alimentos de EE. UU. anunció que retiró su aprobación de Makena. Esto significa que, a partir del 7 de abril de 2023, la HHSC ya no cubre los siguientes productos de Makena ni su autorización clínica previa.

NDC	Drug Name
64011030103	MAKENA 275 MG/1.1 ML AUTOINJCT
00517176701	HYDROXYPROGEST 250 MG/ML VIAL
55150030901	HYDROXYPROGEST 250 MG/ML VIAL
64011030103	MAKENA 275 MG/1.1 ML AUTOINJCT
67457096701	HYDROXYPROGEST 250 MG/ML VIAL
69238179701	HYDROXYPROGEST 250 MG/ML VIAL
71225010401	HYDROXYPROGEST 1,250 MG/5 ML
71225010501	HYDROXYPROGEST 250 MG/ML VIAL

1341 West Mockingbird Lane | Suite 400E | Dallas, Texas 75247
214.266.2100 | Fax 214.266.2150 | parklandhealthplan.com